Thank you for signing up! Did you know with a Digital Subscription to The Star, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ProAssurance Corporation (NYSE: PRA) to The Doctors Company for $25.00 in cash per share is fair to ProAssurance ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of 2seventy bio, Inc. (NASDAQ: TSVT) to Bristol Myers Squibb for $5.00 per share is fair ...

Key man Vini Souza went off at half-time of the victory over Preston North End with a hamstring complaint, while fellow star Gus Hamer was also withdrawn later on after going down for treatment.

The Chargers on Monday released Gus Edwards, making the veteran running back a free agent just before the start of the 2024 New League Year. Edwards joined the Bolts a year ago in free agency but ...

The Chargers are in the market for a new RB2. Los Angeles announced that they would officially release running back Gus Edwards on Friday, clearing $3.125 million of cap room, per OverTheCap. Edwards, ...

LOS ANGELES -- The Chargers informed running back Gus Edwards that they will release him, a source told ESPN's Adam Schefter on Friday. Edwards' release saves the Chargers $3.125 million against ...

LOS ANGELES -- The Chargers informed running back Gus Edwards that they will release him, a source told ESPN's Adam Schefter on Friday. Edwards' release saves the Chargers $3.125 million against the ...

The Chargers have informed running back Gus Edwards that he will be released before the start of NFL free agency, a person with knowledge of the situation not authorized to speak publicly said ...

The Los Angeles Chargers have made another major cap-saving roster cut with the impending release of running back Gus Edwards. ESPN’s Adam Schefter reported the news, which frees roughly $3. ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per share in cash ...